Gilead to Acquire Immuno-Oncology Company Forty Seven for $4.9 Billion

BioSpace | March 02, 2020

Gilead Sciences is buying Forty Seven for $95.50 per share, or a deal value of $4.9 billion. The deal was unanimously approved by both companies’ boards. Gilead picks up Forty Seven’s lead product candidate, magrolimab, a monoclonal antibody in the clinic for several cancers, including myelodysplastic syndrome (MDS), acute myeloid leukemia (AML) and diffuse large B-cell lymphoma (DLBCL). Magrolimab targets CD47. Forty Seven presented positive results from a Phase Ib trial of the drug in MDS and AML at the American Society of Hematology meeting in December 2019.

Spotlight

Growing at a faster pace, in comparison with the previous years, the Indian biotech industry witnessed YoY growth of 57.14 per cent in FY16; the total industry size stood at US$ 11 billionby FY16 and is estimated to reach US$ 11.6 billion by FY17.
Fast-paced growth is likely to continue; the industry is expected to increase in size to US$ 11.6 billion by 2017, driven by a range of factors such as growing demand, intensive R&D activities and strong government initiatives.

Spotlight

Growing at a faster pace, in comparison with the previous years, the Indian biotech industry witnessed YoY growth of 57.14 per cent in FY16; the total industry size stood at US$ 11 billionby FY16 and is estimated to reach US$ 11.6 billion by FY17.
Fast-paced growth is likely to continue; the industry is expected to increase in size to US$ 11.6 billion by 2017, driven by a range of factors such as growing demand, intensive R&D activities and strong government initiatives.

Related News

Biotechnology Leader LuminUltra Submits COVID-19 Clinical Diagnostic Testing Kit for Regulatory Authorization in U.S., Canada

LuminUltra | September 14, 2020

Canada-based biotechnology front-runner LuminUltra announced today that it has submitted its GeneCount® COVID-19 RT-qPCR Assay Kit (COVID-19 Assay) to the U.S. Food and Drug Administration (FDA) for Emergency Use Authorization (EUA) and to Health Canada for an Interim Order (IO). With authorization to use this key testing component, LuminUltra, a leader in field-based molecular diagnostic testing for over 20 years, will provide a complete clinical COVID-19 testing solution that can be customized for testing facilities throughout North America. LuminUltra's accurate GeneCount® COVID-19 RT-qPCR Testing Solution comprises multiple components that together make up an end-to-end solution, including: sample collection kits; isolation reagents; the COVID-19 Assay; and a range of quick-detection qPCR testing devices with software for simple interpretation of COVID-19 test results in under two hours. With the authorization of the COVID-19 Assay, LuminUltra will be able to offer flexibility to appropriate facilities around the world by providing some or all of the necessary COVID-19 testing components from a single, reputable company. This reduces the need to source components from multiple suppliers, allowing facilities to onboard additional testing capacity quickly. Underscoring its reliable supply chain, LuminUltra responded promptly to the Government of Canada's testing needs earlier in the year, and has been a key supplier of the isolation reagents for the national testing program since April, providing 500,000 tests a week.

Read More

INDUSTRIAL IMPACT

Partek and Agilent Partner to Deliver Alissa Customers End-to-End Bioinformatics Workflow

Partek® Incorporated | August 20, 2021

Partek® Incorporated announced today they have entered into an agreement with Agilent to integrate Partek® Flow® bioinformatics software with the Agilent Alissa Clinical Informatics Platform. This integration delivers a complete end-to-end analysis workflow that is robust, flexible, and customizable to meet Agilent customer demands. Partek has also made available the Agilent pipeline for RNA-Seq inside Partek Flow. In addition, the agreement allows Agilent to resell Partek Flow software through the Alissa Portal for a single point solution. “As next-generation sequencing is more broadly adopted for clinical applications, our customers’ software requirements are also expanding. By integrating Partek Flow with the Agilent Alissa Clinical Informatics Platform we will strengthen our overall offering to address diverse applications and workflows across the translational research to clinical testing continuum,” stated Kevin Meldrum, vice president and general manager for the Agilent Genomics Division. About Partek Incorporated Partek Incorporated develops and globally markets quality analysis software and services for life sciences research. Partek software is unique in supporting all major genomic platforms, including bulk and single cell next-generation sequencing. Over eight thousand peer-reviewed scientific papers have used Partek software to streamline the analysis of Gene Expression, miRNA Expression, Copy Number, Allele-Specific Copy Number, LOH, Association, Trio analysis, ChIP-Seq, Single Cell RNA-Seq, RNA-Seq, DNA-Seq, DNA Methylation and qPCR studies. Partek, headquartered in St. Louis, MO, USA, has been turning data into discovery® since 1993.

Read More

MEDICAL

BioAgilytix to Purchase Australia-based 360biolabs®

BioAgilytix | August 17, 2021

BioAgilytix Labs,a leading global contract research laboratory focused on supporting its pharmaceutical and biotech partners in all stages of large molecule drug development, announced today that it signed a definitive agreement to purchase 360biolabs®, the most comprehensive contract research organization in Australia. The transaction will expand BioAgilytix's global footprint into a jurisdiction of choice to commence first-in-human trials (FIH) and early-phase clinical trials and adds further capacity by joining 360biolabs' internationally recognised Quality systems in Melbourne, Victoria with BioAgilytix's existing laboratories in Durham, North Carolina; Boston, Massachusetts; and Hamburg, Germany. Located in Australia's biomedical and clinical research hub, 360biolabs offers world-class virology and immunology expertise, with BSL 2 and 3 laboratories, biomarker and immune monitoring capabilities with a state-of-the-art flow cytometry suite, molecular biology PCR suite and expansive bioanalytical LC-MS/MS small molecule capabilities. "This planned acquisition is part of our strategic growth strategy to expand our capacity, expertise and agility to serve customers across all geographies, and we look forward to welcoming the 360biolabs team and integrating the business," said Jim Datin, President and CEO of BioAgilytix. "Joining forces makes sense for our two organizations, but most importantly for our combined clients and the patients they serve. BioAgilytix and 360biolabs are already culturally aligned in our focus on doing science right, on time, the first time. Together, we will not only create significant scientific synergies but also generate new innovations and help bring future life-changing therapeutics to patients more rapidly around the globe." "From the launch of 360biolabs in 2015, our strategic vision was to build a global speciality laboratory, providing support to enable future medicines for human health," said Angela Luttick, 360biolabs Cofounder and Executive Vice President, Business Development. Added 360biolabs Cofounder and CEO Alistair Draffan, "Finding a like-minded partner, driven by a team-focused culture of excellence with an international reputation, US and European presence, will drive our strategic expansion and support our clients' clinical development programs." Melinda Pryor, Cofounder and Executive Vice President, Clinical stated, "We're excited to join forces with the BioAgilytix team, a company that shares our strong scientific track record and commitment to quality and service. Together, we have the capabilities and capacity to meet all challenges, especially in this time of pandemic, and create enduring opportunities for a brighter future." The Burnet Institute, a global medical research and public health organisation, is a Cofounder and majority shareholder of 360biolabs. Burnet Institute Director and CEO, Professor Brendan Crabb AC said, "Burnet Institute is proud of its involvement in the foundation of 360biolabs. It is the right time, with the growing need for high quality clinical trial support, for a company of the scale, capability, and reputation of 360biolabs to join with BioAgilytix and expand their capacity to service their customers and facilitate high quality translational medical research." The acquisition is subject to Australian Foreign Investment Review Board ("FIRB") requirements and, subject to receipt of FIRB approval, is expected to close in the third quarter of 2021. BioAgilytix selected White & Case as legal counsel to oversee the closing of the acquisition, with Lazard Australia and Allens representing 360biolabs. About BioAgilytix BioAgilytix is a leading bioanalytical testing laboratory specializing in large molecule bioanalysis. With laboratory locations in North Carolina's Research Triangle Park, the Cambridge area of Massachusetts, and Hamburg, Germany, BioAgilytix provides PK, immunogenicity, biomarkers, and cell-based assay services supporting the development and release testing of biologics across a number of industries and disease states. BioAgilytix offers assay development, validation, and sample analysis under non-GLP, GLP, and GCP, as well as GMP quality control testing (i.e., product release testing, stability testing, etc.). BioAgilytix also offers diagnostic testing services at its CLIA-certified, CAP-accredited Boston laboratory. About 360biolabs® 360biolabs® is the leading and most comprehensive specialty laboratory in the Australia & New Zealand region. Our expert pharmacokinetic (PK) and pharmacodynamic (PD) assay services support small molecule, biologic, vaccine and other innovative therapeutic solutions to human health. A world class and industry experienced technical team, known for their ability to successfully deliver technically challenging assays, 360biolabs® supports global Pharmaceutical and biotech companies in a diverse and growing range of therapeutics areas.

Read More